– USA, NY – Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Bespalko to its Board of Directors, effective on March 4, 2021.
“We are delighted to welcome David to the Board of Directors. Given David’s extensive network and experience in the industry, he will add valuable insight to help maximize the value of our DPP platform in the market. We look forward to his collaboration and contributions.” ” said Board Chair, Katherine Davis.
The company also announced that Dr. Mary Lake Polan informed the Board of Directors that she would not stand for reelection to the Board at the 2021 AGM.
Katherine Davis. said, “We also would like to thank Dr. Polan for her service and leadership throughout her tenure and wish her well in her future endeavors.”
About David Bespalko
Mr. Bespalko brings over 35 years of leadership experience in the global in-vitro diagnostics market. Most recently he was Group VP Global Commercial Operations Specialty Diagnostics Group at Thermo Fisher Scientific, which he joined in 2011 as President of Fisher Healthcare. During his tenure there, Mr. Bespalko held additional roles such as President of the Global Anatomical Pathology Division.
Previously, Mr. Bespalko was Corporate VP, North America Commercial Operations at Beckman Coulter. His diagnostics career began in Canada with commercial and general management roles at Baxter Healthcare and Dade Behring. Mr. Bespalko now manages his own consulting firm, BMC, helping early-stage companies and providing executive mentorship.
“I am excited about the opportunity to work with the Chembio team because they have an advanced point-of-care technology and a tremendous opportunity to provide value across decentralized settings in the healthcare landscape,” said Mr. Bespalko. “I am thrilled to join an organization whose mission aligns with my background, focused on expanding and scaling operations to enable greater access to diagnostic testing.”
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever, and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
For more information: https://chembio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
